Skip to main content
Sign In


Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.


Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
Page Size
 |  Displaying page 1 of 5, items 1 to 30 of 135.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
Page Size
 |  Displaying page 1 of 5, items 1 to 30 of 135.
Do you have Parkinson's Disease? 11-1237
To explore the effects of different doses of endurance exercise in people with PD.​
Persons 40-80 who have been diagnosed with Parkinson's Disease and are not yet taking medication or plant to start medication within the next 6 months. You must be willing to begin the exercise program immediately or after a delay of 6 months and willing to do aerobic exercise on a treadmill.
PI: Schenkman, Margaret
  • 720-848-6376
Do you have Atopic Dermatitis (Eczema)? HS-2581
To study eczema
Males and Females between 3 and 80 who have atopic dermatitis or males and females between 8 months and 80 who have a history of, or an active case of eczema hereticum (wide-spread herpes skin infection along with atopic dermatitis.
PI: Leung, Donald
  • 303-398-1409
Better Control of Type 2 Diabetes May Decrease Your Risk for Cardiovascular Disease. 10-0644
To look at the use of an extended release formula of Exenatide compared to a placebo to maintain normal glucose levels. Ultimately to see better control of diabetes and a decrease in cardiovascular disease events.​
Person 18+ with Type 2 Diabetes and take no more than 2 diabetes medications with stale doses for the last 3 months. Must not have a planned or anticipated revascularization procedure, but may have a history of cardiovascular disease and must see your primary care physician at least twice a year.
PI: Rasouli, Neda
  • 303-399-8020 X2059
Type 2 Diabetes and Exercise Research Study 10-1393
To research the effects of an investigational drug on exercise capacity and blood vessel function​.​
Person 30-60 with Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure. Must not have smoked for at least one year and have a BMI between 25-39.9.
PI: Schauer, Irene
  • 720-848-6688
Are you a Non-smoking Adult between the ages of 45 and 85? HS-1883a
We are interested in learning more about smoking related lung disease, and need healthy non-smoking participants.
45-85 years old Non-Hispanic White or African American No smoking history No evidence of lung disease
PI: Bowler, Russ
  • 303-270-2566
Alterations in Lung Microbiome in Acute and Chronic HIV Infection 09-0898
This is a prospective, observational cohort study. Three groups (A1, A2, and B) will be enrolled in parallel.
-Men and women >/= 18 years. -Willing to follow all research requirements -Willing to provide written informed consent -Group A1- acute HIV infection defined as a high risk HIV exposure within the prior 30 days, or recent HIV-1 seroconversion defined as those with a high risk HIV-1 exposure -Group A2- healthy controls: HIV-1 seronegative with no high risk HIV-1 exposure in the prior 30 days and no chronic medical illness -Group B- HIV-1 infection diagnosed by a previous positive antibody or PCR test have been recommended to initiate HAART by their health care provider You should not be in this study if you are a pregnant or planning to become pregnant.
PI: Campbell, Thomas
  • 303-724-0762
Has your child been diagnosed with generalized anxiety disorder? 13-1967
to study sleep and brain activity
• between the ages of 12 & 18 • diagnosed with GAD OR • not diagnosed with any psychological disorders AND who are • right-handed • without orthodontic braces • not taking sleep medications
PI: Mullin, Benjamin
  • 720-777-8006
Volunteers needed to Participate in a Research Study about Rheumatoid Arthritis 01-675
The purpose of this study is to learn more about how rheumatoid arthritis develops by studying people who do not have rheumatoid arthritis. Your participation in this study will help us determine if certain genetic and environmental factors affect the chances of developing RA-related autoantibodies in absence of rheumatoid arthritis.
You may be eligible to participate in the study if: -You are at least 40 years old -You do NOT have Rheumatoid Arthritis (RA)
PI: Norris, Jill
  • 303-724-7510
Restoring Insulin Secretion (RISE) 13-0122
The Children’s Hospital Colorado Clinical Translational Research Center and the National Institutes of Health are conducting a study. This study is aimed at testing whether early treatment is beneficial to kids with early type 2 diabetes and kids at high risk of diabetes.
10-19 years of age, Pubertal, Overweight, Fasting glucose: >90 mg/dl; Impaired glucose tolerance: >140 mg/dl; Pre-diabetes or diagnosed with diabetes for less than 6 months; Metformin
PI: Nadeau, Kristen
  • Susan Gross
Have you experienced a preterm birth? 13-0409
If you participate, the information we learn from you will help us better understand how and why 1 out of 10 pregnancies in the US end in preterm birth.
1. Women ages 18-45 years old 2. willing to meet for 1-2 hours in a focus group setting 3. a mother of a baby who was born more than 3 weeks before your due date
PI: Santoro, Nanette
  • 303-724-2046
Do You Smoke? 12-0181
To figure out how these lung substances work in people who drink too much alcohol, who usually smoke, compared to those who do not drink heavily, but who smoke.
Smoking and nonsmoking males
PI: Burnham, Ellen
  • 303-724-6081
Parents or Legal Guardians of Children with Disabilities 12-1664
Assistive Technology Partners, University of Colorado, Anschutz Medical Campus, is performing a study investigating the impact Socially Assistive Robotics has on motor, communication and cognitive skills of children with disabilities.
Children between the ages of 18 months to 5 years of age Have Significant motor and communication disabilities/delays NOT been diagnosed with blindness or deafness They are without a seizure disorder or with a well-controlled seizure disorder They have been on stable medication regime for the past 12 weeks, if they are currently taking medication.
PI: Sandstrum, Jim
  • 303-315-1287
The Influence of Couples' Conversation on the Heart 13-2188
The purpose of the study is to examine the influence that conversations between married couples have on the functioning of the heart.
Married Christian couples who: • Have been married for at least 1 yr. • Both believe in prayer. • Are not currently taking heart medications. • Do not have heart problems. • Are not pregnant.
PI: Grigsby, Megan
  • 303-556-6020
Help Us Learn About Schizophrenia! 12-1186
Help us learn more about a new drug that may improve thinking and concentration in people with schizophrenia.
We are looking for: Male and female adults who smoke 18-50 years old No previous or current mental illness No drug use Willing to use nicotine patch during study hospital visit If female, willing to use birth control during the study
PI: Freedman, Robert
  • 303-724-6214 or 303-724-7373
Do you use just a rescue inhaler for asthma treatment? 29167/38
Researchers are studying an investigational medication for the treatment of asthma in adults.
Qualifications include: 18-75 years old with asthma Use only a rescue inhaler for asthma treatment
PI: Katial, Rohit
  • 303-398-1966
Exercise for Healthy Aging 14-2207
We need HIV+ and HIV- men and women ages 50-70 who are not currently exercising to join a 6 month exercise program
- HIV+ or HIV- - Aged 50-70 - < 2 days/week of cardiovascular or strength training over the past 6 months - Be willing to come into the Research Center at least 3 days per week for 6 months for supervised exercise training - For women, must be post-menopausal - Body mass index between 20 and 39 - Persons with the following would not be eligible: diabetes; persistent blood pressure >180/100; lung disease requiring 4 or more liters of oxygen with exercise; cancer within 1 year of enrollment; surgery or injury within 6 months of enrollment that would impact an ability to exercise; unstable heart disease; severe liver disease; prior impairment from a stroke or ongoing problems from bone or joint disease that would limit the ability to exercise; moderate to severe dementia. - Persons taking the following medications would NOT be eligible: corticosteroid medications (such as prednisone) by mouth or injection; growth hormone or growth hormone-like therapy (ex: tesamorelin); estrogens; testosterone by injection (patch or gel is ok); chemotherapy - If hepatitis B or C positive, must have an undetectable viral load - If HIV+, must be on antiretroviral therapy for at least 2 years with a mostly undetectable HIV viral load, and no viral load more than 200 copies - If HIV+, must have a CD4 count greater than 200 cells and no AIDS-associated injections in the last 6 months
PI: Erlandson, Kristine
  • 303-724-4941
Research Trial Evaluating a New Drug in Psoriasis: Now Enrolling 14-1692
The study will evaluate an investigational drug compared to a currently approved psoriasis medication. Your participation will provide valuable information to researchers seeking new and improved therapies. You will be given either Humira, placebo, or the investigational drug for up to 28 weeks, after which you may be switched over to the active drug depending on your response.
You may be eligible to participate if 18 years of age or older and have been diagnosed with moderate to severe plaque-type psoriasis for at least 6 months.
PI: Armstrong, April
  • 720-848-3607
Participants with Chronic Kidney Disease and Vitamin D Deficiency Needed for a Research Study 11-0521
This study will examine whether nutritional or active vitamin D supplementation will improve blood vessel function​.
Person 18-80 with chronic kidney disease stage 3B or 4 (estimated GFR 44-15 m;/min) with a vitamin D deficiency or insufficiency.  Women must not be pregnant or breastfeeding.
PI: Kendrick, Jessica
  • 303-724-2275
Trouble Sleeping? HS-2655
Study the effects of two different study drugs, one or two non-drug interventions and/or a combination of both to treat insomnia.
Persons 21+ who have trouble falling or staying asleep at night.
PI: Edinger, Jack
  • 303-398-1938
Give Us a Hand 12-1084
To better understand Multiple Sclerosis in children and teens.
Between the ages of 3-20 AND have Multiple Sclerosis diagnosed before 18 OR Do not have MS
PI: Schreiner, Teri
  • 303-724-3635
Are you an African American with asthma? HS-2805
 We are studying why some African American people have trouble with their asthma despite taking asthma medications.
 Children age 5-17 and non-smoking Adults age18 and older who have asthma symptoms despite asthma treatment • African American ancestry (have at least one    African American grandparent)
PI: Wechsler, MD, Michael
  • 303-398-1443
Peanut and Tree-Nut Allergy Research Study 13-2102
The purpose of this study is to determine how the body's immune system interacts with nuts and other foods to cause allergic reaction.
6-75 years of age. Have a diagnosis of peanut and/or tree-nut allergy made by either skin test or blood tests. Have no known peanut and/or tree-nut allergy.
PI: Dreskin, Stephen
  • 303-724-7193
Research about the Effect of Carbamazepine medication on the Etonogestrel Contraceptive Implant (Implanon®/Nexplanon®) 14-0584
Do you currently have a birth control implant (Implanon®/ Nexplanon®) and are interested in participating in a research study to better understand the effects of certain medication on the implant?
Women ages 18-45 who have had a birth control implant 1 to 3 years • Do not take any medications that are known to effect liver enzymes • Be willing to abstain during the study period or use a secondary form of non-hormonal contraception • Have baseline systolic blood pressure
PI: Lazorwitz, Aaron
  • 303-724-8482
Do you have human growth hormone (hGH) deficiency? 13-2629
Primary: To demonstrate a clinical superiority of MOD-4023 over placebo in terms of decrease in Fat Mass (FM) in adult subjects with Growth Hormone Deficiency Secondary a. To determine the efficacy of MOD-4023 over placebo in other body composition variables (such as lean body mass and waist-to-hip ratio) b. To evaluate the safety and tolerability of MOD-4023 over placebo in adult subjects with GHD c. To determine the IGF-I and IGFBP-3 serum levels
Adult men and women aged 23 to 70 years of age diagnosed with either adult or childhood onset growth hormone deficiency (GHD).
PI: Wierman, Margaret
  • 720-848-7710
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding? 14-1287
The purpose of this study is to gain knowledge on the topic of everyday stressors that affect the lives of children with developmental disabilities, as well as their parents/caregivers
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding?
PI: Benson, Brenna
  • (303) 520-7346
Healthy Female Adults Needed!!! 07-0816
For brain imaging research study on how the brain works with we taste sweets. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 22 to 29 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
Healthy Volunteers Needed for a Research Study on Kidney Disease 14-1209
To understand whether patients with kidney disease with or without a kidney transplant have high levels of microparticles compared to healthy adults. Microparticles are small vesicles that our cells release in response to injury.
Healthy individuals 18 and older. *If you have diabetes, high blood pressure, or heart disease you will not qualify for the study. Pregnant and lactating women are not eligible.
PI: Thurman, Joshua
  • 303-724-8781
  • Karissa Fetrow
Do you have an egg allergy? HS-2764
To see if taking Baked Egg Therapy vs. Oral Immunotherapy may help egg-allergic children tolerate eggs.
males and females 3 to 16 years old, with documented egg allergy, ability to make regular visits to National Jewish Health for up to 2 years.
PI: Leung, Donald
  • 303-398-1618
Be a part of Cancer Research 11-0357
We are looking for women who have not been diagnosed with cancer to participate in a research study. This study plans to learn more about the immune system’s response to cancer. The immune system is a complex network of cells that identify our tissues as “self” or “foreign” as well as normal cells or cancer cells. When normal cells become cancer cells, the cells gain the ability to grow rapidly and can knock down the immune system. This is called immune suppression and is part of what allows a cancer to grow and spread throughout the body. Blood collected in this study will be compared to that of someone with cancer.
To participate you must: *Older than 18 *Be willing to make a one-time blood donation *Not be diagnosed with an immune disease such as diabetes or rheumatoid arthritis You could make a difference in the future of women!
PI: Borges, Virginia
  • 303-724-6077
State of Slim Study Examining Soy 14-1666
The CU Anschutz Health and Wellness Center is seeking volunteers for a new weight loss research study looking at the role of soy protein in weight loss and weight maintenance. The study will last approximately 12 months. Participants will participate in a 16-week State of Slim weight loss program at no charge and receive free soy products or monetary stipends to be used to purchase State of Slim-friendly protein products. Participants will receive DEXA body composition scans, lab work and wellness assessments at no charge.
Are between 18 – 55 years old Are overweight or obese (a BMI ≥27 and ≤40) - Check your BMI at: Are willing to participate in weekly group weight loss classes for 16 weeks and attend five study visits over a 12 month period at the Anschutz Medical Campus Are not vegetarian Are not taking medications for cholesterol Are not diabetic
PI: Hill Ph.D, James
  • 303-724-9198

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
Page Size
 |  Displaying page 1 of 19, items 1 to 30 of 557.
Protocol TitlePI NameInstitution Number
Data pager
Page Size
 |  Displaying page 1 of 19, items 1 to 30 of 557.
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy” – Sponsor SOTIO Sponsor Protocol No. SP005 WIRB Protocol No. 20141765
Flaig, Thomas13-2709
A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, lucitanib, given orally as a single agent to patients with FGFR1-driven lung cancer. Sponsor Protocol No. E-3810-II-02. WIRB Protocol No. 20140760
Camidge, David14-0100
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Therapy in Patients with Metastatic Uveal Melanoma (SUMIT) Sponsor Protocol No. D1344C00001 WIRB Protocol No.20141762
Lewis, Karl14-0108
An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer Sponsor Protocol No. CA209026 WIRB Protocol No. 20140357
Camidge, David14-0243
Leong, Stephen14-0244
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer Sponsor Protocol No. INCB 18424-268 WIRB Protocol No. 20141874
Elias, Anthony14-0356
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects with and without Type 2 Diabetes. Sponsor Protocol No. G-04. WIRB Protocol No. 20150046
Hill, James14-0383
A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)(CheckMate 143: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 143). Sponsor Protocol No. CA209143. WIRB Protocol No. 20140894
Damek, Denise14-0518
Vollmer, Timothy14-0555
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction with Midazolam, and Safety and Tolerability in Patients with Advanced Malignancies Sponsor Protocol No. OPZ009 WIRB Protocol No. 20141700
Gore, Lia14-0589
Evaluation of the Effectiveness of Evolution® Biliary Stent System – Fully Covered. Sponsor Protocol No. 10-014. WIRB Protocol No. 20142167
Shah, Raj14-0602
Camidge, David14-0643
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer Sponsor Protocol No. M12-914 WIRB Protocol No. 20141072
Borges, Virginia14-0799
A Phase 1a/1b Study of the Oral TRK Inhibitor LOXO-101 in Subjects with Adult Solid Tumors. Sponsor Protocol No. LOXO-TRK-14001. WIRB Protocol No. 20142018
Doebele, Robert14-0886
PROspective Study of the IMPACT of Decipher® Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions following Radical Prostatectomy [PRO-IMPACT] Sponsor Protocol No. CU004 WIRB Protocol No. 20142208
Maroni, Paul14-0910
A Double-masked, Placebo-controlled Study with Open-Label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Sponsor Protocol No. CD-IA-MEDI-551-1155 WIRB Protocol No. 20142285
Bennett, Jeffrey14-0926
A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy. Sponsor Protocol No. ALDOXORUBICIN-PE-STS-01. WIRB Protocol No. 20141245
Elias, Anthony14-1004
CEP292- A Performance Evaluation of the Enlite 3 Sensor to Support a Full 168 hours (7days) of Use. Sponsor Protocol No. CEP292/Z25/B. WIRB Protocol No. 20140632
Slover, Robert14-1039
A Performance Evaluation of the Enlite 3 Sensor to Support a Full 168 Hours (7 Days) of Use Study Sponsor Protocol No. CEP292/Z25/B WIRB Protocol No. 20140632
Garg, Satish14-1040
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies Sponsor Protocol No. ORTE-01-14-US WIRB Protocol No. 20141629
Jimeno, Antonio14-1055
A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are &ge; 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy Sponsor Protocol No. M14-358 WIRB Protocol No. 20141655
Pollyea, Daniel14-1142
A Phase 2, Open-label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Squamous Cell Carcinoma of Head and Neck, Lung, or Esophagus. Sponsor Protocol No. KCP-330-006. WIRB Protocol No. 20141119
Jimeno, Antonio14-1152
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors Sponsor Protocol No. CLC-101 WIRB Protocol No. 20141911
Eckhardt, Sue14-1201
A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the Eye Sponsor Protocol No. 32-007 WIRB Protocol No. 20111432
Palestine, Alan14-1279
Oliver, Scott14-1281
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin in Adults with Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis (TURQUOISE-CPB). Sponsor Protocol No. M14-227. WIRB Protocol No. 20141710
Everson, Greg14-1284
Menard-Katcher, Paul14-1285
A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS). Sponsor Protocol No. 101MS409. WIRB Protocol No. 20141062
Alvarez, Enrique14-1295
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC) Sponsor Protocol # C26002 WIRB Protocol # 20141183
Messersmith, Wells14-1305
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC). Sponsor Protocol No. C26003. WIRB Protocol No. 20141223
Messersmith, Wells14-1306

Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more